Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.

Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.

Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.

Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.

The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.

Fresenius SE is primarily active in the healthcare industry.

Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.

Fresenius SE & Co KGaA의 P/E 비율은 11.58입니다.

Fresenius SE & Co KGaA의 P/S 비율은 0.85입니다.

Fresenius SE & Co KGaA에 대한 AlleAktien 품질 점수는 2/10입니다.

예상되는 Fresenius SE & Co KGaA 매출은 21.98 조. EUR입니다.

예상되는 Fresenius SE & Co KGaA 이익은 1.62 조. EUR입니다.

Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.

Fresenius SE & Co KGaA은(는) 연간 1번의 배당을 통해 0.26 EUR의 배당금을 지급합니다.

Fresenius SE & Co KGaA는 연간 1번의 배당금을 지급합니다.

Fresenius SE & Co KGaA의 ISIN은 DE0005785604입니다.

Fresenius SE & Co KGaA의 WKN은 578560입니다.

Fresenius SE & Co KGaA의 티커는 FRE.DE입니다.

지난 12개월 동안 Fresenius SE & Co KGaA은(는) 0.92 EUR 의 배당금을 지급했습니다. 이는 약 2.76 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Fresenius SE & Co KGaA은(는) 0.97 EUR의 배당금을 지급할 것으로 예상됩니다.

Fresenius SE & Co KGaA의 현재 배당 수익률은 2.76 %입니다.

Fresenius SE & Co KGaA은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Fresenius SE & Co KGaA은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0.97 EUR의 배당금이 예상됩니다. 이는 배당수익률 2.9 %에 해당합니다.

Fresenius SE & Co KGaA은 '건강' 섹터에 속합니다.

Fresenius SE & Co KGaA의 마지막 배당금을 0.92 EUR만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Fresenius SE & Co KGaA는 0.26 EUR를 배당금으로 지급했습니다.

Fresenius SE & Co KGaA의 배당금은 EUR에 지급됩니다.